Navigation Links
Standard Heart Drugs Won't Ease Pulmonary Hypertension
Date:5/18/2011

WEDNESDAY, May 18 (HealthDay News) -- Although commonly used to treat heart disease, aspirin and simvastatin offer no benefit to patients suffering from pulmonary arterial hypertension, or PAH, a progressive disease characterized by increased blood pressure in the arteries of the lungs, according to new research.

In a study funded by the U.S. National Institutes of Health, researchers divided 65 patients into four groups: one receiving aspirin; one taking simvastatin; one receiving both drugs; and one in which patients received a placebo (or dummy pill).

"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population," said Dr. Steven Kawut, study lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine.

After taking the assigned medication for six months, patients were asked to see how far they could walk in six minutes. The distance tended to be shorter in the simvastatin group, and no difference was seen between the aspirin and placebo patients.

Following these early results, the U.S. National Heart, Lung, and Blood Institute discontinued the study based on a recommendation from the Data and Safety Monitoring Board.

"The results of this study do not support the routine treatment of PAH with these medications," Kawut said in an American Thoracic Society news release.

The findings are scheduled to be presented Wednesday at the American Thoracic Society international conference in Denver.

PAH, which is incurable, causes shortness of breath, dizziness and fatigue, and can lead to heart failure and death.

The researchers concluded that both aspirin and simvastatin may be prescribed for usual clinical indications in patients with PAH, but should not be administered specifically to treat PAH.

"The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled [randomized clinical trials] in humans before recommending their use," Kawut said.

Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on treatments for pulmonary arterial hypertension.

-- Mary Elizabeth Dallas

SOURCE: American Thoracic Society, news release, May 18, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. eHealthObjects chooses Elsevier/Gold Standard drug database
2. Human Factors/Ergonomics research leads to improved bunk bed safety standards
3. IOM recommends standards to achieve reliable clinical practice guidelines
4. Quality standards for widely used medicines strengthened
5. Federal Supply Schedule pricing added to ProspectoRx from Elsevier/Gold Standard
6. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
7. Community oncology: Ensuring the best standards of care
8. FDA Panel Recommends Tougher Standards for External Defibrillators
9. FDA Looking at Tougher Standards for External Defibrillators
10. FDA Looking for Tougher Standards for External Defibrillators
11. Universal standards proposed for prescription container labels to help reduce medication misuse
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Standard Heart Drugs Won't Ease Pulmonary Hypertension
(Date:5/6/2016)... Miami, Florida (PRWEB) , ... May 06, 2016 , ... ... scratching their heads as they try to get rid of the bugs and keep ... left trying to figure out how to protect their kids and their homes from ...
(Date:5/6/2016)... Irving, TX (PRWEB) , ... May 06, 2016 ... ... from offices in Irving, TX has announced the latest beneficiary of their ongoing ... a local family battling childhood leukemia. Young Mason McGaughey faces many more months ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... of a master charity program created to support and assist the people of ... days, working closely with nonprofit organizations and community leaders. Their desire is to ...
(Date:5/6/2016)... and LONDON, UK (PRWEB) , ... May 06, 2016 , ... ... for his success in changing the way the pharmaceutical industry conducts clinical trials. This ... the world’s most influential people in pharma, and he was honored as a Tech ...
(Date:5/6/2016)... ... , ... The joy associated with Mother’s Day is mixed with worry and fear for new ... across the country. For the first time ever, the March of Dimes and ... their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through a glass ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... -- Ampronix is excited to announce that we now stock the ( most advanced surgical and ... UHD camera was released to the consumer market in March 2016. Photo - ... ... ... The finely crafted GP-UH532 camera is the newest iteration of Panasonic,s 1080p HD ...
(Date:5/6/2016)... According to a new ... (Sso-PCR, Ssp-PCR, NGS, Sanger,s Sequencing), Products & Services ... (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", ... to reach USD 753.9 Million by 2021 from ... of 7.1% from 2016 to 2021. ...
(Date:5/6/2016)... May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2016 third quarter dividend of $0.17 per ... over the amount paid a year ago. The dividend ... of the close of business on June 10, 2016. ... Hill-Rom is a leading global medical technology company with ...
Breaking Medicine Technology: